Abstract
Contact tracing is critical to limiting the spread of pandemics such as COVID-19, but most protocols only “forward-trace” to notify people who were recently exposed. Using a stochastic branching process model, we find that “bidirectional” tracing to identify infector individuals robustly outperforms forward-only approaches across a wide range of scenarios. The addition of rapid smartphone-based exposure notification offers few benefits over conventional manual tracing alone unless uptake of the digital system is near-universal. However, as long as exposure events can be detected by nearly all smartphones, the combination of manual and digital with bidirectional tracing more than doubles the probability of controlling outbreaks across three epidemiological scenarios. Implementing combined bidirectional tracing may be critical to controlling COVID-19 without more costly interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by gifts from the Reid Hoffman Foundation and the Open Philanthropy Project (to K.M.E.) and cluster time granted by the COVID-19 HPC-1 consortium (MCB20071 to K.M.E.). E.C.A. was supported by a fellowship from the Open Philanthropy Project. A.L.L. is supported by the Drexel Endowment (NC State University).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
3
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos